The present study aimed to examine a weakly electric fish Gnathonemus petersii (G. petersii) as a candidate model organism of glutamatergic theory of schizophrenia. The idea of G. petersii elevating the modeling of schizophrenia symptoms is based on the fish's electrolocation and electrocommunication abilities. Fish were exposed to the NMDA antagonist ketamine in two distinct series differing in the dose of ketamine. The main finding revealed ketamine-induced disruption of the relationship between electric signaling and behavior indicating impairment of fish navigation. Moreover, lower doses of ketamine significantly increased locomotion and erratic movement and higher doses of ketamine reduced the number of electric organ discharges indicating successful induction of positive schizophrenia-like symptoms and disruption of fish navigation. Additionally, a low dose of haloperidol was used to test the normalization of the positive symptoms to suggest a predictive validity of the model. However, although successfully induced, positive symptoms were not normalized using the low dose of haloperidol; hence, more doses of the typical antipsychotic haloperidol and probably also of a representative of atypical antipsychotic drugs need to be examined to confirm the predictive validity of the model.
Schizophrenia is a severe neuropsychiatric disease associated with substantially higher mortality. Reduced life expectancy in schizophrenia relates to an increased prevalence of metabolic disturbance, and antipsychotic medication is a major contributor. Molecular mechanisms underlying adverse metabolic effects of antipsychotics are not fully understood; however, adipose tissue homeostasis deregulation appears to be a critical factor. We employed mass spectrometry-based untargeted proteomics to assess the effect of chronic olanzapine, risperidone, and haloperidol treatment in visceral adipose tissue of prenatally methylazoxymethanol (MAM) acetate exposed rats, a well-validated neurodevelopmental animal model of schizophrenia. Bioinformatics analysis of differentially expressed proteins was performed to highlight the pathways affected by MAM and the antipsychotics treatment. MAM model was associated with the deregulation of the TOR (target of rapamycin) signalling pathway. Notably, alterations in protein expression triggered by antipsychotics were observed only in schizophrenia-like MAM animals where we revealed hundreds of affected proteins according to our two-fold threshold, but not in control animals. Treatments with all antipsychotics in MAM rats resulted in the downregulation of mRNA processing and splicing, while drug-specific effects included among others upregulation of insulin resistance (olanzapine), upregulation of fatty acid metabolism (risperidone), and upregulation of nucleic acid metabolism (haloperidol). Our data indicate that deregulation of several energetic and metabolic pathways in adipose tissue is associated with APs administration and is prominent in MAM schizophrenia-like model but not in control animals.
- MeSH
- antipsychotika terapeutické užití MeSH
- haloperidol farmakologie terapeutické užití MeSH
- krysa rodu rattus MeSH
- methylazoxymethanolacetát farmakologie MeSH
- modely nemocí na zvířatech MeSH
- nitrobřišní tuk účinky léků embryologie metabolismus MeSH
- olanzapin farmakologie terapeutické užití MeSH
- potkani Sprague-Dawley MeSH
- proteomika MeSH
- risperidon farmakologie terapeutické užití MeSH
- schizofrenie farmakoterapie MeSH
- signální transdukce účinky léků MeSH
- těhotenství MeSH
- TOR serin-threoninkinasy metabolismus MeSH
- tuková tkáň účinky léků metabolismus MeSH
- zpožděný efekt prenatální expozice chemicky indukované metabolismus MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Mortality in psychiatric patients with severe mental illnesses reaches a 2-3 times higher mortality rate compared to the general population, primarily due to somatic comorbidities. A high prevalence of cardiovascular morbidity can be attributed to the adverse metabolic effects of atypical antipsychotics (atypical APs), but also to metabolic dysregulation present in drug-naïve patients. The metabolic aspects of neurodevelopmental schizophrenia-like models are understudied. This study evaluated the metabolic phenotype of a methylazoxymethanol (MAM) schizophrenia-like model together with the metabolic effects of three APs [olanzapine (OLA), risperidone (RIS) and haloperidol (HAL)] administered via long-acting formulations for 8 weeks in female rats. Body weight, feed efficiency, serum lipid profile, gastrointestinal and adipose tissue-derived hormones (leptin, ghrelin, glucagon and glucagon-like peptide 1) were determined. The lipid profile was assessed in APs-naïve MAM and control cohorts of both sexes. Body weight was not altered by the MAM model, though cumulative food intake and feed efficiency was lowered in the MAM compared to CTR animals. The effect of the APs was also present; body weight gain was increased by OLA and RIS, while OLA induced lower weight gain in the MAM rats. Further, the MAM model showed lower abdominal adiposity, while OLA increased it. Serum lipid profile revealed MAM model-induced alterations in both sexes; total, HDL and LDL cholesterol levels were increased. The MAM model did not exert significant alterations in hormonal parameters except for elevation in leptin level. The results support intrinsic metabolic dysregulation in the MAM model in both sexes, but the MAM model did not manifest higher sensitivity to metabolic effects induced by antipsychotic treatment.
- MeSH
- antipsychotika farmakologie terapeutické užití MeSH
- haloperidol farmakologie terapeutické užití MeSH
- metabolismus lipidů účinky léků MeSH
- metabolom účinky léků MeSH
- methylazoxymethanolacetát analogy a deriváty MeSH
- modely nemocí na zvířatech * MeSH
- olanzapin farmakologie terapeutické užití MeSH
- potkani Sprague-Dawley MeSH
- risperidon farmakologie terapeutické užití MeSH
- schizofrenie chemicky indukované farmakoterapie metabolismus MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Gestational methylazoxymethanol acetate (MAM) treatment produces offspring with adult phenotype relevant to schizophrenia, including positive- and negative-like symptoms, cognitive deficits, dopaminergic dysfunction, structural and functional abnormalities. Here we show that adult rats prenatally treated with MAM at gestational day 17 display significant increase in dopamine D3 receptor (D3) mRNA expression in prefrontal cortex (PFC), hippocampus and nucleus accumbens, accompanied by increased expression of dopamine D2 receptor (D2) mRNA exclusively in the PFC. Furthermore, a significant change in the blood perfusion at the level of the circle of Willis and hippocampus, paralleled by the enlargement of lateral ventricles, was also detected by magnetic resonance imaging (MRI) techniques. Peripubertal treatment with the non-euphoric phytocannabinoid cannabidiol (30 mg/kg) from postnatal day (PND) 19 to PND 39 was able to reverse in MAM exposed rats: i) the up-regulation of the dopamine D3 receptor mRNA (only partially prevented by haloperidol 0.6 mg/kg/day); and ii) the regional blood flow changes in MAM exposed rats. Molecular modelling predicted that cannabidiol could bind preferentially to dopamine D3 receptor, where it may act as a partial agonist according to conformation of ionic-lock, which is highly conserved in GPCRs. In summary, our results demonstrate that the mRNA expression of both dopamine D2 and D3 receptors is altered in the MAM model; however only the transcript levels of D3 are affected by cannabidiol treatment, likely suggesting that this gene might not only contribute to the schizophrenia symptoms but also represent an unexplored target for the antipsychotic activity of cannabidiol.
- MeSH
- antipsychotika farmakologie MeSH
- haloperidol chemie farmakologie MeSH
- kanabidiol chemie farmakologie MeSH
- magnetická rezonanční tomografie MeSH
- methylazoxymethanolacetát toxicita MeSH
- modely nemocí na zvířatech MeSH
- molekulární modely MeSH
- mozek diagnostické zobrazování účinky léků MeSH
- mozkový krevní oběh MeSH
- potkani Sprague-Dawley MeSH
- puberta MeSH
- receptory dopaminu D2 chemie genetika metabolismus MeSH
- receptory dopaminu D3 chemie genetika metabolismus MeSH
- regulace genové exprese MeSH
- schizofrenie chemicky indukované diagnostické zobrazování farmakoterapie genetika MeSH
- simulace molekulární dynamiky MeSH
- těhotenství MeSH
- zpožděný efekt prenatální expozice MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- MeSH
- citalopram farmakologie MeSH
- farmakoterapie MeSH
- farmakovigilance MeSH
- haloperidol farmakologie MeSH
- lidé MeSH
- srdeční arytmie farmakoterapie MeSH
- syndrom dlouhého QT * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
Prolonged QT interval is an independent risk factor for development of ventricular arrhythmias. Haloperidol is one of the drugs inducing QT prolongation. Previous studies showed that haloperidol affects not only QT duration but also heart rate (RR interval). The present work focused on relationship between QT and RR and its changes under acute and chronic haloperidol administration. The study included 14 male guinea pigs divided into control and haloperidol-treated group. After 21-days administration of haloperidol or vehiculum, electrograms in isolated hearts were recorded. QT/RR and dQT/dRR coupling were calculated. Chronic haloperidol administration significantly decreases the coupling between QT and RR. Acute haloperidol exposure significantly decreases the dQT/dRR coupling in both treated and untreated guinea pig hearts. Flatter QT/RR relationship reveals a lack of QT adaptation to increased heart rate. It should be emphasized that in such situation ECG recording will not show significant QT prolongation evaluated according to clinical rules. However, if QT interval does not adapt to increased heart rate sufficiently, the risk of ventricular arrhythmias may be increased despite practically normal QT interval length. The results are supported by findings in biochemical analyses, which proved eligibility of the used model.
V článku je diskutován význam edukace pacientů se schizofrenií a jejich rodinných příslušníků při zahájení terapie a v průběhu udržovací léčby dlouhodobě působícími injekčními antipsychotiky. Předně je důležité vybrat vhodnou subpopulaci pacientů pro tento způsob léčby. Edukaci by měl provádět zkušený profesionál, který má sám k této léčbě pozitivní postoj. V průběhu diskuze je třeba s pacienty a jejich rodinnými příslušníky probrat výhody (ale také nevýhody) terapie dlouhodobě působícími injekčními antipsychotiky spíše než se zaměřit jen na způsob aplikace. Edukovat je vhodné i další členy terapeutického týmu. V edukaci je třeba pokračovat po celou dobu léčby, protože jedině tak lze dosáhnout lepších a stabilnějších výsledků celé terapie.
The article discusses the importance of education aimed to patients with schizophrenia and their family members during the initiation and during the course of maintenance treatment with long-acting injectable antipsychotics. It is very important to choose the optimal subpopulation of patients for this type of treatment. Education should be led by experienced professional with positive attitude to this treatment. It is necessary to discuss with patients and their family members the advantages (and disadvantages) of treatment with long-acting injectable antipsychotics rather than only injection procedure. Education is needed for other staff members too. The continuation of education is necessary during the whole course of treatment because only this procedure can provide better and more stable treatment outcome.
- MeSH
- antipsychotika aplikace a dávkování terapeutické užití MeSH
- flufenazin aplikace a dávkování farmakologie MeSH
- flupenthixol aplikace a dávkování farmakologie MeSH
- haloperidol aplikace a dávkování farmakologie MeSH
- injekce MeSH
- klopenthixol aplikace a dávkování farmakologie MeSH
- léky s prodlouženým účinkem MeSH
- lidé MeSH
- olanzapin aplikace a dávkování farmakologie terapeutické užití MeSH
- risperidon analogy a deriváty aplikace a dávkování farmakologie MeSH
- schizofrenie * farmakoterapie MeSH
- udržovací chemoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
Haloperidol is an antipsychotic agent that primarily acts as an antagonist of D2 dopamine receptors. Besides other receptor systems, it targets sigma 1 receptors (σ1Rs) and inositol 1,4,5-trisphosphate receptors (IP3Rs). Aim of this work was to investigate possible changes in IP3Rs and σ1Rs resulting from haloperidol treatment and to propose physiological consequences in differentiated NG-108 cells, i.e., effect on cellular plasticity. Haloperidol treatment resulted in up-regulation of both type 1 IP3Rs (IP3R1s) and σ1Rs at mRNA and protein levels. Haloperidol treatment did not alter expression of other types of IP3Rs. Calcium release from endoplasmic reticulum (ER) mediated by increased amount of IP3R1s elevated cytosolic calcium and generated ER stress. IP3R1s were bound to σ1Rs, and translocation of this complex from ER to nucleus occurred in the group of cells treated with haloperidol, which was followed by increased nuclear calcium levels. Haloperidol-induced changes in cytosolic, reticular, and nuclear calcium levels were similar when specific σ1 blocker -BD 1047- was used. Changes in calcium levels in nucleus, ER, and cytoplasm might be responsible for alterations in cellular plasticity, because length of neurites increased and number of neurites decreased in haloperidol-treated differentiated NG-108 cells.
- MeSH
- antipsychotika farmakologie MeSH
- buněčná diferenciace účinky léků fyziologie MeSH
- haloperidol farmakologie MeSH
- inositol-1,4,5-trisfosfát - receptory metabolismus MeSH
- krysa rodu rattus MeSH
- myši MeSH
- nádorové buněčné linie MeSH
- neuroplasticita účinky léků fyziologie MeSH
- receptory sigma metabolismus MeSH
- vazba proteinů účinky léků fyziologie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
AIMS: Haloperidol is an antipsychotic agent and acts as dopamine D2 receptor (D2R) antagonist, as a prototypical ligand of sigma1 receptors (Sig1R) and it increases expression of type 1 IP3 receptors (IP3R1). However, precise mechanism of haloperidol action on cardiomyocytes through dopaminergic signaling was not described yet. This study investigated a role of dopamine receptors in haloperidol-induced increase in IP3R1 and Sig1R, and compared physiological effect of melperone and haloperidol on basic heart parameters in rats. MATERIALS AND METHODS: We used differentiated NG-108 cells and H9c2 cells. Gene expression, Western blot and immunofluorescence were used to evaluate haloperidol-induced differences; proximity ligation assay (PLA) and immunoprecipitation to determine interactions of D1/D2 receptors. To evaluate cardiac parameters, Wistar albino male rats were used. KEY FINDINGS: We have shown that antagonism of D2R with either haloperidol or melperone results in upregulation of both, IP3R1 and Sig1R, which is associated with increased D2R, but reduced D1R expression. Immunofluorescence, immunoprecipitation and PLA support formation of heteromeric D1/D2 complexes in H9c2 cells. Treatment with haloperidol (but not melperone) caused decrease in systolic and diastolic blood pressure and significant increase in heart rate. SIGNIFICANCE: Because D1R/D2R complexes can engage Gq-like signaling in other experimental systems, these results are consistent with the possibility that disruption of D1R/D2R complex in H9c2 cells might cause a decrease in IP3R1 activity, which in turn may account for the increase expression of IP3R and Sig1R. D2R is probably not responsible for changes in cardiac parameters, since melperone did not have any effect.
- MeSH
- antagonisté dopaminu D2 farmakologie MeSH
- antagonisté dopaminu farmakologie MeSH
- buněčné linie MeSH
- haloperidol farmakologie MeSH
- potkani Wistar MeSH
- receptory dopaminu D1 genetika metabolismus MeSH
- receptory dopaminu D2 genetika metabolismus MeSH
- regulace genové exprese účinky léků MeSH
- signální transdukce účinky léků MeSH
- srdce účinky léků MeSH
- srdeční frekvence účinky léků MeSH
- vazba proteinů účinky léků MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Článek shrnuje základní údaje o dlouhodobě působících neboli depotních antipsychoticích, která jsou v současnosti dostupná v České republice. Jedná se o čtyři antipsychotika I. generace (flufenazin, flupentixol, haloperidol a zuklopentixol) a čtyři antipsychotika II. generace (aripiprazol, olanzapin, risperidon a paliperidon). Zaměřuje se zejména na zahájení léčby a dávkování. Diskutovány jsou rovněž i základní výhody a nevýhody depotní formy, její účinnost v prevenci relapsu a riziko nežádoucích účinků ve srovnání s perorální formou antipsychotik.
The article summarizes basic data concerning long-acting injectable or depot antipsychotics, which are currently available in theCzech Republic. They include four first generation antipsychotics (fluphenazine, flupenthixol, haloperidol and zucklopenthixol)and four second generation antipsychotics (aripiprazole, olanzapine, risperidone and paliperidone). It focuses especially on thetreatment initiation and dosage regimen. Basic advantages and disadvantages of depot formulation are discussed as well as itsefficacy in the prevention of relapse and the risk of adverse-events compared to oral formulation of antipsychotics.
- MeSH
- adherence a compliance při léčbě MeSH
- antagonisté dopaminu aplikace a dávkování farmakokinetika farmakologie MeSH
- antipsychotika * aplikace a dávkování farmakokinetika farmakologie MeSH
- aripiprazol aplikace a dávkování farmakokinetika farmakologie MeSH
- benzodiazepiny aplikace a dávkování farmakokinetika farmakologie MeSH
- flufenazin aplikace a dávkování farmakokinetika farmakologie MeSH
- flupenthixol aplikace a dávkování farmakokinetika farmakologie MeSH
- haloperidol aplikace a dávkování farmakokinetika farmakologie MeSH
- injekce intramuskulární MeSH
- léky s prodlouženým účinkem MeSH
- lidé MeSH
- risperidon analogy a deriváty aplikace a dávkování farmakokinetika farmakologie MeSH
- schizofrenie a poruchy s psychotickými rysy farmakoterapie MeSH
- udržovací chemoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
- přehledy MeSH